Respirology : official journal of the Asian Pacific Society of Respirology
-
Randomized Controlled Trial Multicenter Study Comparative Study
Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
The efficacy and safety of indacaterol, a novel inhaled once daily ultra long-acting β(2) -agonist was evaluated in COPD patients in six Asian countries/areas. This study was primarily designed to obtain the regulatory approval of indacaterol in Japan. ⋯ Indacaterol provided clinically significant bronchodilation and improvements in dyspnoea and health status in Asian COPD patients.